key: cord-0700568-4z5e291f
authors: Carugno, Andrea; Gambini, Daniele Mario; Raponi, Francesca; Vezzoli, Pamela; Locatelli, Andrea Gustavo C.; Di Mercurio, Marco; Test, Elisa Robustelli; Sena, Paolo
title: COVID-19 and biologics for psoriasis: a high-epidemic area experience - Bergamo, Lombardy, Italy
date: 2020-05-06
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2020.04.165
sha: 9e1d1334ad02220437912bf17a08303e65e2acd1
doc_id: 700568
cord_uid: 4z5e291f

nan

Key words: Psoriasis, Biologic therapy, COVID-19, Severe Acute Respiratory Syndrome -14

Coronavirus -2 (SARS-CoV-2), Dermatology, Skin 15 with COVID-19 and it has become a serious public health emergency. 1 The first case in our 4 hospital was identified on February 21 st , 2020. 2 5

Information is still limited regarding the new coronavirus and its impact on chronic 6 immunosuppressive therapy patients. In a pre-coronavirus era, respiratory infection rates for 7 biologic therapy patients were comparable to placebo. 3 8

As suggested by the Italian Society of Dermatologists (SIDeMaST), 4 we advise patients 9 treated with biological drugs to carefully comply with hygiene rules, protective devices use, 10 to maintain social distancing and to not spontaneously suspend ongoing therapy but to inform 11 the dermatologist in case of symptoms. We report our experience with patients treated with 12 biological therapy for psoriasis in Bergamo, an area of high epidemic rates for COVID-19. 13

Patients being treated at the psoriasis outpatient service of the Bergamo Hospital live in 15

Bergamo (86.2%, n=137), Milan (6.3%, n=10), Brescia (4.4%, n=7), Lecco (1.9%, n=3), Lodi 16 (1.3%, n=2) all Lombardy region areas with a high incidence rate of COVID-19 infections. 5 17 All patients were contacted by telephone or underwent a dermatological visit 40 to 45 days 18 after the beginning of the coronavirus epidemic (population characteristics are shown in Table  19 1). Twenty-five patients (15.7%) reported contacting established (positive nasal swab test) or 20 suspected cases of COVID-19. Eighteen of these 25 patients (72.0%) developed COVID-19 21 suspected symptoms (15 mild, 3 moderate, Table 1 ). 22

Six patients contacted us to report respiratory symptoms; as a precaution, given the limited 23 information available on the risk due to COVID-19, we temporarily discontinue therapy for 24 up to 30 days after the symptoms resolved. One patient reported serious symptoms that 25 required hospitalization (Pneumococcal pneumonia with negative COVID-19 nasal swab). 1

Three patients without symptoms stopped therapy on their own and reported worsening of 2 psoriasis; all resumed treatment after receiving reassurances. Twenty-three patients reported 3

having had symptoms consistent with COVID-19 (22 mild, 1 moderate), but did not stop 4 therapy. There were no significant demographic or comorbidity differences between patients 5 who had COVID-19 like symptoms and those who did not (Table 2 ). 6 7

We observed a significant risk of infection in our area, especially for those who had close 8 contacts with potential COVID-19 patients. Therefore, we think it is essential to advise and 9 empower patients on activities that can help to limit the risk of infection. Fortunately, serious 10 cases of COVID-19 infection have not been reported and even patients who continued therapy 11 showed almost exclusively mild symptoms. As a precaution we decided on a case by case 12 basis whether to discontinue therapy, however we did not observe a more aggressive course Patients who had drug suspended (%, n) 5.6 (9/159) Table 1 .

Characteristics of psoriatic patients on biological therapy. * In March 2020 almost only hospitalized patients were tested with COVID-19 nasal swab (n=0/1 positive nasal swab/hospitalized patients) ** Suspected COVID-19 symptoms: "Mild": flu-like symptoms, cough, low-grade fever, anosmia/ageusia, resolved in ≤7 days without hospitalization. "Moderate": flu-like symptoms, cough, low-grade fever, anosmia/ageusia, resolved in 8-16 days without hospitalization. "Severe": serious symptoms that required hospitalization; one patient reported serious symptoms that required hospitalization (Pneumococcal pneumonia with negative COVID-19 nasal swab). SD: standard deviation. Characteristics of patients with suspected COVID-19 symptoms. * Myocardial infarction, stroke, diabetes, obesity, dyslipidemia or non-alcoholic fatty liver disease. ** Suspected COVID-19 symptoms: "Mild": flu-like symptoms, cough, low-grade fever, anosmia/ageusia, resolved in ≤7 days without hospitalization. "Moderate": flu-like symptoms, cough, low-grade fever, anosmia/ageusia, resolved in 8-16 days without hospitalization. "Severe": serious symptoms that required hospitalization: one patient reported serious symptoms that required hospitalization (Pneumococcal pneumonia with negative COVID-19 nasal swab). SD: standard deviation. Statistical analysis was performed by t-test and chi-squared test. Significance value was set at p < 0.05.

Critical care utilization for the COVID-19 outbreak in 20

Italy: early experience and forecast during an emergency response